«A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease». Alzheimer Disease and Associated Disorders21 (2): 136–43. 2007. doi:10.1097/WAD.0b013e318065c495. PMID17545739.
«Lack of evidence for the efficacy of memantine in mild Alzheimer disease». Archives of Neurology68 (8): 991–8. August 2011. doi:10.1001/archneurol.2011.69. PMID21482915.
Hong, Michael P.; Erickson, Craig A. (2019-08-03). «Investigational drugs in early-stage clinical trials for autism spectrum disorder». Expert Opinion on Investigational Drugs (Informa UK Limited) 28 (8): 709–718. doi:10.1080/13543784.2019.1649656. ISSN1354-3784. PMID31352835.
«From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs». Drug Testing and Analysis6 (7–8): 614–32. 2014. doi:10.1002/dta.1620. PMID24678061.
«Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse». Neuropharmacology53 (6): 699–723. November 2007. doi:10.1016/j.neuropharm.2007.07.013. PMID17904591.
«Pathologically activated therapeutics for neuroprotection». Nature Reviews. Neuroscience8 (10): 803–8. October 2007. doi:10.1038/nrn2229. PMID17882256.
«The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner». Neuroscience Letters306 (1–2): 81–4. June 2001. doi:10.1016/S0304-3940(01)01872-9. PMID11403963.
«Memantine agonist action at dopamine D2High receptors». Synapse62 (2): 149–53. February 2008. doi:10.1002/syn.20472. PMID18000814.
«Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine». The European Journal of Neuroscience19 (8): 2212–20. April 2004. doi:10.1111/j.0953-816X.2004.03297.x. PMID15090047.
«Memantine hydrochloride». Nature Reviews. Drug Discovery3 (2): 109–10. February 2004. doi:10.1038/nrd1311. PMID15040575.
«NADAC as of 2019-02-27». Centers for Medicare and Medicaid Services (στα Αγγλικά). Αρχειοθετήθηκε από το πρωτότυπο στις 6 Μαρτίου 2019. Ανακτήθηκε στις 3 Μαρτίου 2019.
«A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease». Alzheimer Disease and Associated Disorders21 (2): 136–43. 2007. doi:10.1097/WAD.0b013e318065c495. PMID17545739.
«Lack of evidence for the efficacy of memantine in mild Alzheimer disease». Archives of Neurology68 (8): 991–8. August 2011. doi:10.1001/archneurol.2011.69. PMID21482915.
Hong, Michael P.; Erickson, Craig A. (2019-08-03). «Investigational drugs in early-stage clinical trials for autism spectrum disorder». Expert Opinion on Investigational Drugs (Informa UK Limited) 28 (8): 709–718. doi:10.1080/13543784.2019.1649656. ISSN1354-3784. PMID31352835.
«From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs». Drug Testing and Analysis6 (7–8): 614–32. 2014. doi:10.1002/dta.1620. PMID24678061.
«Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse». Neuropharmacology53 (6): 699–723. November 2007. doi:10.1016/j.neuropharm.2007.07.013. PMID17904591.
«Pathologically activated therapeutics for neuroprotection». Nature Reviews. Neuroscience8 (10): 803–8. October 2007. doi:10.1038/nrn2229. PMID17882256.
«The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner». Neuroscience Letters306 (1–2): 81–4. June 2001. doi:10.1016/S0304-3940(01)01872-9. PMID11403963.
«Memantine agonist action at dopamine D2High receptors». Synapse62 (2): 149–53. February 2008. doi:10.1002/syn.20472. PMID18000814.
«Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine». The European Journal of Neuroscience19 (8): 2212–20. April 2004. doi:10.1111/j.0953-816X.2004.03297.x. PMID15090047.
«Memantine hydrochloride». Nature Reviews. Drug Discovery3 (2): 109–10. February 2004. doi:10.1038/nrd1311. PMID15040575.
«NADAC as of 2019-02-27». Centers for Medicare and Medicaid Services (στα Αγγλικά). Αρχειοθετήθηκε από το πρωτότυπο στις 6 Μαρτίου 2019. Ανακτήθηκε στις 3 Μαρτίου 2019.